Clinical Trial: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008378) titled 'A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis' on May 20.

Brief Summary: This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis

Intervention: BIOLOGICAL: P-CD19CD20-ALLO1 Cells

P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.

DRUG: Cyclop...